CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...